How a neuroscientist invests in biopharma
About this episode
Equity analyst Laura Nelson Carney discusses her unique approach to investing in biopharma using her neuroscience background.
Equity analyst Laura Nelson Carney uses her PhD in neuroscience to help spot medical innovation around the world. She brings a deep understanding of science to health care investing, using her research and drug development experience to help identify breakthrough drugs. And today, she's looking beyond biotechs in Boston and San Francisco and turning her attention to China as a growing source of innovation. #CapGroupGlobal This content is intended to highlight issues and be of a general nature. It should not be considered advice, an endorsement or a recommendation. Products mentioned are not an offer of the product and may not be available for sale or purchase in all countries. All investments have risk, and you may lose money. Past results are not a guarantee of future results. Statements attributed to an individual represent the opinions of that individual as of the date published and do not necessarily reflect the opinions of Capital Group or its affiliates. This content is published by Capital Client Group, Inc., and copyrighted to Capital Group and affiliates, 2026, all rights reserved. For more information, including our detailed disclosures, visit…
More episodes of Capital Ideas Podcast
- Stress testing AI Bulls vs. Bears
- How GM's Chair and CEO is redefining what's possible at a legacy company
- Investing after the Iran war ends
- Beyond AI: Investing in the physical economy
- Why municipal bonds can win on an after-tax basis
- All that glitters: What's driving up gold prices?
Explore listener stats, chart rankings, contacts and more on the Capital Ideas Podcast podcast page.